{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T13:38:20Z","timestamp":1792849100263,"version":"4.5.0"},"reference-count":107,"publisher":"American Chemical Society (ACS)","issue":"20","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","award":["CN00000041"],"award-info":[{"award-number":["CN00000041"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM49758"],"award-info":[{"award-number":["GM49758"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Domp\u00e9 Farmaceutici SpA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We herein describe the structure-based design, synthesis and biological evaluation of a new class of histone deacetylase 6 (HDAC6) inhibitors guided by X-ray crystal structures of our previously identified compounds 13-15. X-ray co-crystal structures of second-generation inhibitors 19b (Subseries I) and 20b (Subseries II) within zHDAC6 CD2 confirmed that these compounds behave as highly potent HDAC6 inhibitors with the ability to engage the S531 residue in the L2 loop HDAC6 catalytic domain. Western-blot analysis confirmed the target engagement in cell-based settings, through the increase of acetylated tubulin levels, without significant variation in the histone acetylation status. Compound 20b extensively reduced the viability of A549 cells in both 2- and 3-dimensional cell cultures, through the activation of pro-autophagic pathways. In addition, HDAC6 inhibition impaired the nucleation of stress-granules, confirming the ability of these compounds to modulate liquid\u2212liquid phase separation, an emerging HDAC6-driven hallmark in cancer.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c02004","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:01:45Z","timestamp":1791828105000},"page":"24496-24523","source":"Crossref","is-referenced-by-count":1,"title":["Structure-Based Design of HDAC6 Inhibitors Targeting the L2 Pocket: Modulating Autophagy and Liquid\u2212Liquid Phase Separation in Lung Cancer"],"prefix":"10.1021","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3985-1812","authenticated-orcid":true,"given":"Simona","family":"Barone","sequence":"first","affiliation":[{"name":"University of Naples Federico II , , Via D. Montesano 49 , ,","place":["Naples, Italy, 80131"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7581-0073","authenticated-orcid":true,"given":"Abraham","family":"Eafa","sequence":"additional","affiliation":[{"name":"University of Pennsylvania , , , ,","place":["Philadelphia, Pennsylvania, United States, 19104"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Bello","sequence":"additional","affiliation":[{"name":"University of Naples Federico II , , Via D. Montesano 49 , ,","place":["Naples, Italy, 80131"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gessica","family":"Filocamo","sequence":"additional","affiliation":[{"name":"Exiris s.r.l , Via di Castel Romano, 100 , ,","place":["Rome, Italy, 00128"]},{"name":". , Via di Castel Romano, 100 , ,","place":["Rome, Italy, 00128"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Alberico","sequence":"additional","affiliation":[{"name":"University of Naples Federico II , , Via D. Montesano 49 , ,","place":["Naples, Italy, 80131"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Cassese","sequence":"additional","affiliation":[{"name":"University of Naples Federico II , , Via D. Montesano 49 , ,","place":["Naples, Italy, 80131"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Guadagni","sequence":"additional","affiliation":[{"name":"University of Naples Federico II , , Via D. Montesano 49 , ,","place":["Naples, Italy, 80131"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Rebmann","sequence":"additional","affiliation":[{"name":"Cancer Drug Development Group , , ,","place":["Heidelberg, Germany, 69120"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-5649","authenticated-orcid":true,"given":"Emanuela","family":"Cosentino","sequence":"additional","affiliation":[{"name":"Exiris s.r.l , Via di Castel Romano, 100 , ,","place":["Rome, Italy, 00128"]},{"name":". , Via di Castel Romano, 100 , ,","place":["Rome, Italy, 00128"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana Goulart","family":"Stollmaier","sequence":"additional","affiliation":[{"name":"University of Pennsylvania , , , ,","place":["Philadelphia, Pennsylvania, United States, 19104"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1761-4143","authenticated-orcid":true,"given":"Aubry K.","family":"Miller","sequence":"additional","affiliation":[{"name":"Cancer Drug Development Group , , ,","place":["Heidelberg, Germany, 69120"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6288-2681","authenticated-orcid":true,"given":"Vincenzo","family":"Summa","sequence":"additional","affiliation":[{"name":"University of Naples Federico II , , Via D. Montesano 49 , ,","place":["Naples, Italy, 80131"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longlong","family":"Wang","sequence":"additional","affiliation":[{"name":"ETH Zu\u0308rich , , ,","place":["Zu\u0308rich, Switzerland, 8093"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Panza","sequence":"additional","affiliation":[{"name":"University of Naples Federico II , , Via D. Montesano 49 , ,","place":["Naples, Italy, 80131"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0194-5212","authenticated-orcid":true,"given":"David W.","family":"Christianson","sequence":"additional","affiliation":[{"name":"University of Pennsylvania , , , ,","place":["Philadelphia, Pennsylvania, United States, 19104"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-3773","authenticated-orcid":true,"given":"Margherita","family":"Brindisi","sequence":"additional","affiliation":[{"name":"University of Naples Federico II , , Via D. Montesano 49 , ,","place":["Naples, Italy, 80131"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"1","key":"2026102408070238900_cit1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s42003-018-0214-4","article-title":"Structural and Chemical Biology of Deacetylases for Carbohydrates, Proteins, Small Molecules and Histones","volume":"1","author":"Bu\u0308rger","year":"2018","journal-title":"Commun. Biol."},{"issue":"3","key":"2026102408070238900_cit2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of Chromatin by Histone Modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res."},{"issue":"2","key":"2026102408070238900_cit3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s12276-020-0382-4","article-title":"A Short Guide to Histone Deacetylases Including Recent Progress on Class II Enzymes","volume":"52","author":"Park","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"4","key":"2026102408070238900_cit4","doi-asserted-by":"publisher","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of Histone Acetylation: The Histone Deacetylase Enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"9","key":"2026102408070238900_cit5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone Deacetylases and Their Inhibitors in Cancer, Neurological Diseases and Immune Disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"2026102408070238900_cit6","doi-asserted-by":"publisher","first-page":"116884","DOI":"10.1016\/j.ejmech.2024.116884","article-title":"Tackling Triple Negative Breast Cancer with HDAC Inhibitors: 6 Is the Isoform","volume":"279","author":"Guadagni","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"2026102408070238900_cit7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.20517\/cdr.2024.103","article-title":"HDAC-Driven Mechanisms in Anticancer Resistance: Epigenetics and Beyond","volume":"20","author":"Minisini","year":"2024","journal-title":"Cancer Drug Resist."},{"issue":"10","key":"2026102408070238900_cit8","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1091\/mbc.e08-02-0139","article-title":"HDAC4 Promotes Growth of Colon Cancer Cells via Repression of P21","volume":"19","author":"Wilson","year":"2008","journal-title":"Mol. Biol. Cell"},{"issue":"1","key":"2026102408070238900_cit9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-019-1127-7","article-title":"Role of HDACs in Normal and Malignant Hematopoiesis","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer"},{"issue":"6","key":"2026102408070238900_cit10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3390\/ph15060667","article-title":"HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer","volume":"15","author":"Maccallini","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"01","key":"2026102408070238900_cit11","doi-asserted-by":"publisher","first-page":"14934","DOI":"10.4172\/2167-7700.1000111","article-title":"Cancer Epigenetics: Mechanisms and Crosstalk of a HDAC Inhibitor, Vorinostat","volume":"02","author":"Huang R","year":"2013","journal-title":"Chemother.:Open Access"},{"issue":"1","key":"2026102408070238900_cit12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/icb.2011.96","article-title":"Modulation of Antigen-presenting Cells by HDAC Inhibitors: Implications in Autoimmunity and Cancer","volume":"90","author":"Woan","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"2026102408070238900_cit13","doi-asserted-by":"publisher","first-page":"118541","DOI":"10.1016\/j.biopha.2025.118541","article-title":"Insights into Histone Deacetylase Inhibitors-Induced Cell Death in Cancer Cell Lines","volume":"191","author":"Fuentes-Baile","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"2026102408070238900_cit14","doi-asserted-by":"publisher","first-page":"1576781","DOI":"10.3389\/fonc.2025.1576781","article-title":"Advances of HDAC Inhibitors in Tumor Therapy: Potential Applications through Immune Modulation","volume":"15","author":"Tian","year":"2025","journal-title":"Front. Oncol."},{"issue":"19","key":"2026102408070238900_cit15","doi-asserted-by":"publisher","first-page":"17796","DOI":"10.1021\/acs.jmedchem.4c01817","article-title":"Hydrazide-Based Class I Selective HDAC Inhibitors Completely Reverse Chemoresistance Synergistically in Platinum-Resistant Solid Cancer Cells","volume":"67","author":"Kraft","year":"2024","journal-title":"J. Med. Chem."},{"key":"2026102408070238900_cit16","unstructured":"Accessed on June 22, 2026. https:\/\/www.federalregister.gov\/documents\/2022\/03\/24\/2022-06182\/secura-bio-inc-withdrawal-of-approval-of-new-drug-application-for-farydak-panobinostat-capsules-10."},{"issue":"4","key":"2026102408070238900_cit17","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1039\/D5RA09034B","article-title":"HDAC Inhibitors as Anticancer Drugs: Chemical Diversity, Clinical Trials, Challenges and Perspectives","volume":"16","author":"Abdallah","year":"2026","journal-title":"RSC Adv."},{"issue":"4","key":"2026102408070238900_cit18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4155\/fmc.12.3","article-title":"Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed","volume":"4","author":"Gryder","year":"2012","journal-title":"Future Med. Chem."},{"issue":"1","key":"2026102408070238900_cit19","doi-asserted-by":"publisher","first-page":"35880","DOI":"10.1038\/s41598-025-19717-w","article-title":"Adverse Drug Reaction Profiles of Histone Deacetylase Inhibitors","volume":"15","author":"Begum","year":"2025","journal-title":"Sci. Rep."},{"issue":"1","key":"2026102408070238900_cit20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","article-title":"Advances in Targeting Histone Deacetylase for Treatment of Solid Tumors","volume":"17","author":"Shi","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"2026102408070238900_cit21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1021\/acs.jmedchem.9b00924","article-title":"Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases","volume":"63","author":"Brindisi","year":"2020","journal-title":"J. Med. Chem."},{"issue":"4","key":"2026102408070238900_cit22","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1021\/acs.jmedchem.1c02067","article-title":"Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology","volume":"65","author":"Barone","year":"2022","journal-title":"J. Med. Chem."},{"issue":"31","key":"2026102408070238900_cit23","doi-asserted-by":"publisher","first-page":"10842","DOI":"10.1021\/ja102758v","article-title":"Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A","volume":"132","author":"Butler","year":"2010","journal-title":"J. Am. Chem. Soc."},{"issue":"9","key":"2026102408070238900_cit24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nchembio.2134","article-title":"Histone Deacetylase 6 Structure and Molecular Basis of Catalysis and Inhibition","volume":"12","author":"Hai","year":"2016","journal-title":"Nat. Chem. Biol."},{"issue":"17","key":"2026102408070238900_cit25","doi-asserted-by":"publisher","first-page":"8054","DOI":"10.1021\/acs.jmedchem.8b01013","article-title":"Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity","volume":"61","author":"Porter","year":"2018","journal-title":"J. Med. Chem."},{"key":"2026102408070238900_cit26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jare.2022.06.009","article-title":"Rational Design of Synthetically Tractable HDAC6\/HSP90 Dual Inhibitors to Destroy Immune-Suppressive Tumor Microenvironment","volume":"46","author":"Wu","year":"2023","journal-title":"J. Adv. Res."},{"key":"2026102408070238900_cit27","doi-asserted-by":"publisher","first-page":"1340585","DOI":"10.3389\/fmicb.2024.1340585","article-title":"Unveiling the Modulation of Pseudomonas Aeruginosa Virulence and Biofilm Formation by Selective Histone Deacetylase 6 Inhibitors","volume":"15","author":"Barone","year":"2024","journal-title":"Front. Microbiol."},{"issue":"6","key":"2026102408070238900_cit28","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1021\/acsinfecdis.6c00195","article-title":"F2F-202, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor, Behaves as an Arrow with Multiple Tips against Azole-Resistant C. Albicans : Modulation of Yeast-to-Hyphae Transition, Trailing Effect, and Oxidative Stress","volume":"12","author":"Barone","year":"2026","journal-title":"ACS Infect. Dis."},{"key":"2026102408070238900_cit29","doi-asserted-by":"publisher","first-page":"118806","DOI":"10.1016\/j.ejmech.2026.118806","article-title":"Fine-Tuning the Combination of Novel Spirocyclic Capping Moieties and Heterocyclic Zinc Binding Groups for Selective HDAC6 Inhibition: Design, Synthesis, Kinetic and Biological Studies","volume":"311","author":"Barone","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"2026102408070238900_cit30","doi-asserted-by":"publisher","first-page":"175349","DOI":"10.1016\/j.ejphar.2022.175349","article-title":"Efficacy of Selective Histone Deacetylase 6 Inhibition in Mouse Models of Pseudomonas Aeruginosa Infection: A New Glimpse for Reducing Inflammation and Infection in Cystic Fibrosis","volume":"936","author":"Brindisi","year":"2022","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"2026102408070238900_cit31","doi-asserted-by":"publisher","first-page":"10122","DOI":"10.1021\/acs.jmedchem.5c03139","article-title":"GV-001, An Oral Available Histone Deacetylase 6 Inhibitor for the Treatment of Autosomal Dominant Polycystic Kidney Disease","volume":"69","author":"Wu","year":"2026","journal-title":"J. Med. Chem."},{"issue":"11","key":"2026102408070238900_cit32","doi-asserted-by":"publisher","first-page":"10991","DOI":"10.1021\/acs.jmedchem.4c03231","article-title":"Structural Optimization of 1,3-Diaryl-1,2,4-Triazole-Capped Histone Deacetylase 6 Inhibitors to Obtain Novel Antiesophageal Cancer Candidates","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"11","key":"2026102408070238900_cit33","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1021\/acsmedchemlett.0c00395","article-title":"Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, Synthesis, Structural Analysis, and Biological Evaluation","volume":"11","author":"Saraswati","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"14","key":"2026102408070238900_cit34","doi-asserted-by":"publisher","first-page":"10080","DOI":"10.1021\/acs.jmedchem.3c00977","article-title":"Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity","volume":"66","author":"Liu","year":"2023","journal-title":"J. Med. Chem."},{"issue":"2","key":"2026102408070238900_cit35","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1021\/acsptsci.4c00456","article-title":"Spirotetrahydroisoquinoline-Based Histone Deacetylase Inhibitors as New Antifibrotic Agents: Biological Evaluation in Human Fibroblasts from Bronchoalveolar Lavages of Idiopathic Pulmonary Fibrosis Patients","volume":"8","author":"Fontana","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"2026102408070238900_cit36","doi-asserted-by":"publisher","first-page":"109785","DOI":"10.1016\/j.bioorg.2026.109785","article-title":"Discovery of Novel HDAC6 Inhibitors Based on the Diphenyl-1,2,4-Oxadiazole Scaffold with Potential Efficacy in Alleviating Inflammation- and Chemotherapy- Associated Mechanical Hypersensitivity","volume":"175","author":"Yin","year":"2026","journal-title":"Bioorg. Chem."},{"issue":"18","key":"2026102408070238900_cit37","doi-asserted-by":"publisher","first-page":"10339","DOI":"10.1021\/acs.jmedchem.9b01888","article-title":"Multicomponent Synthesis, Binding Mode, and Structure\u2212Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups","volume":"63","author":"Re\u00dfing","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026102408070238900_cit38","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1021\/acs.jmedchem.9b01540","article-title":"Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6","volume":"63","author":"Osko","year":"2020","journal-title":"J. Med. Chem."},{"key":"2026102408070238900_cit39","doi-asserted-by":"publisher","first-page":"104462","DOI":"10.1016\/j.bioorg.2020.104462","article-title":"Investigation of the Effect of Different Linker Chemotypes on the Inhibition of Histone Deacetylases (HDACs)","volume":"106","author":"Linciano","year":"2021","journal-title":"Bioorg. Chem."},{"key":"2026102408070238900_cit40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.sbi.2019.01.004","article-title":"Structure, Mechanism, and Inhibition of the Zinc-Dependent Histone Deacetylases","volume":"59","author":"Porter","year":"2019","journal-title":"Curr. Opin. Struct. Biol."},{"key":"2026102408070238900_cit41","doi-asserted-by":"publisher","first-page":"108055","DOI":"10.1016\/j.phrs.2025.108055","article-title":"Selective HDAC6 Inhibition by Mesinostat Impairs Tumor Growth and Stemness in Triple-Negative Breast Cancer","volume":"222","author":"Bello","year":"2025","journal-title":"Pharmacol. Res."},{"key":"2026102408070238900_cit42","doi-asserted-by":"publisher","first-page":"117634","DOI":"10.1016\/j.ejmech.2025.117634","article-title":"Challenging Triple Negative Breast Cancer through HDAC6 Selective Inhibition: Novel Cap-Group Identification, Structure-Activity Relationships, Computational and Biological Studies","volume":"292","author":"Barone","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"2026102408070238900_cit43","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1021\/acsptsci.4c00031","article-title":"2-(Difluoromethyl)-1,3,4-Oxadiazoles: The Future of Selective Histone Deacetylase 6 Modulation?","volume":"7","author":"Ko\u0308nig","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"11","key":"2026102408070238900_cit44","doi-asserted-by":"publisher","first-page":"5885","DOI":"10.3390\/ijms25115885","article-title":"Mechanistic and Structural Insights on Difluoromethyl-1,3,4-Oxadiazole Inhibitors of HDAC6","volume":"25","author":"Cellupica","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"2026102408070238900_cit45","doi-asserted-by":"publisher","first-page":"13821","DOI":"10.1021\/acs.jmedchem.3c01345","article-title":"Difluoromethyl-1,3,4-Oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase 6","volume":"66","author":"Ko\u0308nig","year":"2023","journal-title":"J. Med. Chem."},{"issue":"3","key":"2026102408070238900_cit46","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1021\/acsmedchemlett.0c00532","article-title":"Evaluation of 5-(Trifluoromethyl)-1,2,4-Oxadiazole-Based Class IIa HDAC Inhibitors for Huntington\u2019s Disease","volume":"12","author":"Stott","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"2026102408070238900_cit47","doi-asserted-by":"publisher","first-page":"115907","DOI":"10.1016\/j.ejmech.2023.115907","article-title":"5-(Trifluoromethyl)-1,2,4-Oxadiazole (TFMO)-Based Highly Selective Class IIa HDAC Inhibitors Exhibit Synergistic Anticancer Activity in Combination with Bortezomib","volume":"263","author":"Asfaha","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"2026102408070238900_cit48","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/scibx.2013.323","article-title":"Trifluoromethyloxadiazole (TFMO)-Containing Compounds to Identify Class IIa Histone Deacetylase (HDAC) Inhibitors","volume":"6","year":"2013","journal-title":"Science-Business eXchange"},{"issue":"3","key":"2026102408070238900_cit49","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1021\/acsmedchemlett.5c00033","article-title":"Development of Ethyl-Hydrazide-Based Selective Histone Deacetylase 6 (HDAC6) PROTACs","volume":"16","author":"Stopper","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"issue":"18","key":"2026102408070238900_cit50","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202400194","article-title":"Heterocycles\u2212Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen Years","volume":"19","author":"Raucci","year":"2024","journal-title":"ChemMedChem"},{"issue":"14","key":"2026102408070238900_cit51","doi-asserted-by":"publisher","first-page":"14171","DOI":"10.1021\/acs.jmedchem.5c01677","article-title":"Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic Potential","volume":"68","author":"Raucci","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026102408070238900_cit52","unstructured":"Accessed on June 22, 2026. https:\/\/gco.iarc.fr\/today\/en\/dataviz\/pieprevalence?mode=cancer&types=2&group_populations=1."},{"key":"2026102408070238900_cit53","unstructured":"Accessed on June 22, 2026. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer."},{"key":"2026102408070238900_cit54","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3389\/fonc.2017.00193","article-title":"Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification","volume":"7","author":"Inamura","year":"2017","journal-title":"Front. Oncol."},{"issue":"3","key":"2026102408070238900_cit55","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.cllc.2016.03.003","article-title":"A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study","volume":"17","author":"Planchard","year":"2016","journal-title":"Clin. Lung Cancer"},{"key":"2026102408070238900_cit56","unstructured":"Cheung, J.; Lehar, S. M.; Chiu, H.; Irving, B.; Maecker, H.; Mariathasan, S.; Wu, Y.\n          Anti-PD-L1 Antibodies and Their Use to Enhance T-Cell Function. WO2009US67104, 2009."},{"key":"2026102408070238900_cit57","unstructured":"Hermann, A.\n          ; Anti-ctla-4 antibodies and uses thereof, WO 2019023482 A1, 2018."},{"key":"2026102408070238900_cit58","unstructured":"Korman, A. J.\n          ; Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics, WO 2006121168 A1, 2006."},{"key":"2026102408070238900_cit59","unstructured":"Sadineni, V.\n          ; Compositions comprising a combination of nivolumab and ipilimumab, US Patent 10,512,689 B2, 2016."},{"issue":"1","key":"2026102408070238900_cit60","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.phrs.2011.09.002","article-title":"Ipilimumab: A Novel Immunostimulatory Monoclonal Antibody for the Treatment of Cancer","volume":"65","author":"Graziani","year":"2012","journal-title":"Pharmacol. Res."},{"issue":"3","key":"2026102408070238900_cit61","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1039\/D4MD00800F","article-title":"Lazertinib: Breaking the Mold of Third-Generation EGFR Inhibitors","volume":"16","author":"Patel","year":"2025","journal-title":"RSC Med. Chem."},{"issue":"9","key":"2026102408070238900_cit62","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1080\/17512433.2019.1649136","article-title":"Dacomitinib for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer","volume":"12","author":"Santarpia","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"2026102408070238900_cit63","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3389\/fonc.2019.00804","article-title":"Accurate Classification of Non-Small Cell Lung Cancer (NSCLC) Pathology and Mapping of EGFR Mutation Spatial Distribution by Ambient Mass Spectrometry Imaging","volume":"9","author":"Zhang","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"2026102408070238900_cit64","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","article-title":"Advances in Molecular Pathology and Therapy of Non-Small Cell Lung Cancer","volume":"10","author":"Huang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"2026102408070238900_cit65","doi-asserted-by":"publisher","first-page":"1230824","DOI":"10.3389\/fphar.2023.1230824","article-title":"Drug Resistance Mechanism and Reversal Strategy in Lung Cancer Immunotherapy","volume":"14","author":"Xu","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"5","key":"2026102408070238900_cit66","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/CM9.0000000000002991","article-title":"Recent Advances and Remaining Challenges in Lung Cancer Therapy","volume":"137","author":"Barr","year":"2024","journal-title":"Chin. Med. J."},{"issue":"3","key":"2026102408070238900_cit67","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The Evolving Landscape of Biomarkers for Checkpoint Inhibitor Immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"2026102408070238900_cit68","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.tips.2014.08.001","article-title":"Drugging the HDAC6\u2212HSP90 Interplay in Malignant Cells","volume":"35","author":"Kra\u0308mer","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"issue":"5","key":"2026102408070238900_cit69","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1093\/emboj\/cdg115","article-title":"HDAC-6 Interacts with and Deacetylates Tubulin and Microtubules in Vivo","volume":"22","author":"Zhang","year":"2003","journal-title":"EMBO J."},{"issue":"1","key":"2026102408070238900_cit70","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.canlet.2014.07.041","article-title":"HDAC6 Sustains Growth Stimulation by Prolonging the Activation of EGF Receptor through the Inhibition of Rabaptin-5-Mediated Early Endosome Fusion in Gastric Cancer","volume":"354","author":"Park","year":"2014","journal-title":"Cancer Lett."},{"issue":"3","key":"2026102408070238900_cit71","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc4897","article-title":"Multiple Screening Approaches Reveal HDAC6 as a Novel Regulator of Glycolytic Metabolism in Triple-Negative Breast Cancer","volume":"7","author":"Dowling","year":"2021","journal-title":"Sci. Adv."},{"key":"2026102408070238900_cit72","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.semcdb.2022.09.009","article-title":"Immunomodulatory Properties of HDAC6 Inhibitors in Cancer Diseases: New Chances for Sophisticated Drug Design and Treatment Optimization","volume":"154","author":"Biersack","year":"2024","journal-title":"Semin. Cell Dev. Biol."},{"key":"2026102408070238900_cit73","doi-asserted-by":"publisher","first-page":"123219","DOI":"10.1016\/j.ijbiomac.2023.123219","article-title":"Curriculum Vitae of HDAC6 in Solid Tumors","volume":"230","author":"Zheng","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"2026102408070238900_cit74","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12672-026-04391-9","article-title":"Role of HDAC6 in Carcinomas","volume":"17","author":"Chen","year":"2026","journal-title":"Discover Oncol."},{"issue":"1","key":"2026102408070238900_cit75","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1038\/s41598-020-60271-4","article-title":"HDAC6, Modulated by MiR-206, Promotes Endometrial Cancer Progression through the PTEN\/AKT\/MTOR Pathway","volume":"10","author":"Zheng","year":"2020","journal-title":"Sci. Rep."},{"key":"2026102408070238900_cit76","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.humpath.2017.11.010","article-title":"The Immunohistochemical Expression and Potential Prognostic Value of HDAC6 and AR in Invasive Breast Cancer","volume":"75","author":"Li","year":"2018","journal-title":"Hum. Pathol."},{"issue":"3","key":"2026102408070238900_cit77","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.21873\/anticanres.14927","article-title":"Up-Regulation of HDAC6 Results in Poor Prognosis and Chemoresistance in Patients With Advanced Ovarian High-Grade Serous Carcinoma","volume":"41","author":"Yano","year":"2021","journal-title":"Anticancer Res."},{"issue":"2","key":"2026102408070238900_cit78","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.tranon.2019.11.001","article-title":"Inhibition of HDAC6 Attenuates Tumor Growth of Non-Small Cell Lung Cancer","volume":"13","author":"Deskin","year":"2020","journal-title":"Transl. Oncol."},{"issue":"1","key":"2026102408070238900_cit79","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41698-025-00949-y","article-title":"HDAC6 Facilitates LUAD Progression by Inducing EMT and Enhancing Macrophage Polarization towards the M2 Phenotype","volume":"9","author":"Jiang","year":"2025","journal-title":"npj Precis. Oncol."},{"issue":"1","key":"2026102408070238900_cit80","doi-asserted-by":"publisher","first-page":"10.46439\/cancerbiology.2.015","DOI":"10.46439\/cancerbiology.2.015","article-title":"Implications of the USP10-HDAC6 Axis in Lung Cancer - A Path to Precision Medicine","volume":"2","author":"Zhang","year":"2021","journal-title":"J. Cancer Biol."},{"issue":"5","key":"2026102408070238900_cit81","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41419-020-2519-8","article-title":"The USP10-HDAC6 Axis Confers Cisplatin Resistance in Non-Small Cell Lung Cancer Lacking Wild-Type P53","volume":"11","author":"Hu","year":"2020","journal-title":"Cell Death Dis."},{"issue":"4","key":"2026102408070238900_cit82","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007588","article-title":"Dual Molecule Targeting HDAC6 Leads to Intratumoral CD4+ Cytotoxic Lymphocytes Recruitment through MHC-II Upregulation on Lung Cancer Cells","volume":"12","author":"Ducellier","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"2026102408070238900_cit83","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3892\/or.2016.4811","article-title":"HDAC6 Promotes Cell Proliferation and Confers Resistance to Gefitinib in Lung Adenocarcinoma","volume":"36","author":"Wang","year":"2016","journal-title":"Oncol. Rep."},{"issue":"17","key":"2026102408070238900_cit84","doi-asserted-by":"publisher","first-page":"8054","DOI":"10.1021\/acs.jmedchem.8b01013","article-title":"Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity","volume":"61","author":"Porter","year":"2018","journal-title":"J. Med. Chem."},{"issue":"18","key":"2026102408070238900_cit85","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1021\/acs.biochem.2c00332","article-title":"Aromatic Ring Fluorination Patterns Modulate Inhibitory Potency of Fluorophenylhydroxamates Complexed with Histone Deacetylase 6","volume":"61","author":"Watson","year":"2022","journal-title":"Biochemistry"},{"issue":"11","key":"2026102408070238900_cit86","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1021\/acsmedchemlett.1c00425","article-title":"Role of Fluorination in the Histone Deacetylase 6 (HDAC6) Selectivity of Benzohydroxamate-Based Inhibitors","volume":"12","author":"Sandrone","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"issue":"10","key":"2026102408070238900_cit87","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1016\/j.drudis.2020.07.017","article-title":"Fsp3: A New Parameter for Drug-Likeness","volume":"25","author":"Wei","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"21","key":"2026102408070238900_cit88","doi-asserted-by":"publisher","first-page":"6752","DOI":"10.1021\/jm901241e","article-title":"Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success","volume":"52","author":"Lovering","year":"2009","journal-title":"J. Med. Chem."},{"issue":"51","key":"2026102408070238900_cit89","doi-asserted-by":"publisher","first-page":"13459","DOI":"10.1073\/pnas.1718823114","article-title":"Unusual Zinc-Binding Mode of HDAC6-Selective Hydroxamate Inhibitors","volume":"114","author":"Porter","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"2026102408070238900_cit90","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41392-021-00678-1","article-title":"Liquid\u2212Liquid Phase Separation in Human Health and Diseases","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"2026102408070238900_cit91","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.70122","article-title":"Liquid\u2212Liquid Phase Separation in Major Hallmarks of Cancer","volume":"59","author":"Xie","year":"2026","journal-title":"Cell Prolif."},{"issue":"4","key":"2026102408070238900_cit92","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41568-022-00444-7","article-title":"Liquid\u2212Liquid Phase Separation Drives Cellular Function and Dysfunction in Cancer","volume":"22","author":"Mehta","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"23","key":"2026102408070238900_cit93","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71308","article-title":"Phase Separation of PHLDB2 Drives EMT and Tumor Progression in Triple-Negative Breast Cancer","volume":"14","author":"Zhang","year":"2025","journal-title":"Cancer Med."},{"issue":"11","key":"2026102408070238900_cit94","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1038\/s43018-024-00816-y","article-title":"Phase Separation of Phospho-HDAC6 Drives Aberrant Chromatin Architecture in Triple-Negative Breast Cancer","volume":"5","author":"Lu","year":"2024","journal-title":"Nat. Cancer"},{"issue":"1","key":"2026102408070238900_cit95","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41589-018-0180-7","article-title":"Acetylation of Intrinsically Disordered Regions Regulates Phase Separation","volume":"15","author":"Saito","year":"2019","journal-title":"Nat. Chem. Biol."},{"issue":"17","key":"2026102408070238900_cit96","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.1021\/ma070428j","article-title":"Regioregular Polymerization of Fluorine-Containing Epoxides","volume":"40","author":"Sakakibara","year":"2007","journal-title":"Macromolecules"},{"key":"2026102408070238900_cit97","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/bs.mie.2019.06.028","article-title":"Methods for the Expression, Purification, and Crystallization of Histone Deacetylase 6\u2212Inhibitor Complexes","author":"Osko","year":"2019"},{"issue":"1","key":"2026102408070238900_cit98","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1107\/S0907444905036693","article-title":"Scaling and Assessment of Data Quality","volume":"62","author":"Evans","year":"2006","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"issue":"7","key":"2026102408070238900_cit99","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1107\/S0907444913000061","article-title":"How Good Are My Data and What Is the Resolution?","volume":"69","author":"Evans","year":"2013","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"issue":"4","key":"2026102408070238900_cit100","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1107\/S0907444911007773","article-title":"Data Processing and Analysis with the AutoPROC Toolbox","volume":"67","author":"Vonrhein","year":"2011","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"issue":"4","key":"2026102408070238900_cit101","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1107\/S0907444911007773","article-title":"Data Processing and Analysis with the AutoPROC Toolbox","volume":"67","author":"Vonrhein","year":"2011","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"issue":"4","key":"2026102408070238900_cit102","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser Crystallographic Software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"issue":"4","key":"2026102408070238900_cit103","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1107\/S0907444912001308","article-title":"Towards Automated Crystallographic Structure Refinement with. Phenix.Refine","volume":"68","author":"Afonine","year":"2012","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"issue":"10","key":"2026102408070238900_cit104","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","article-title":"Macromolecular Structure Determination Using X-Rays, Neutrons and Electrons: Recent Developments in Phenix","volume":"75","author":"Liebschner","year":"2019","journal-title":"Acta Crystallogr. D Struct. Biol."},{"issue":"1","key":"2026102408070238900_cit105","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/pro.3330","article-title":"MolProbity: More and Better Reference Data for Improved All-atom Structure Validation","volume":"27","author":"Williams","year":"2018","journal-title":"Protein Sci."},{"issue":"13","key":"2026102408070238900_cit106","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/cmdc.202000149","article-title":"Design and Synthesis of Dihydroxamic Acids as HDAC6\/8\/10 Inhibitors","volume":"15","author":"Morgen","year":"2020","journal-title":"ChemMedChem"},{"key":"2026102408070238900_cit107","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/bs.mie.2025.01.061","article-title":"TR-FRET Assay for Profiling HDAC10 Inhibitors and PROTACs","volume":"715","author":"Remans","year":"2025","journal-title":"Methods Enzymol."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c02004","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/24496\/68824725\/jm6c02004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/24496\/68824725\/jm6c02004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T13:23:31Z","timestamp":1792848211000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/20\/24496\/5449247\/Structure-Based-Design-of-HDAC6-Inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":107,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2026,10,12]]},"published-print":{"date-parts":[[2026,10,22]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c02004","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]}}}